TNFRSF8 and classic Hodgkin lymphoma: Those anti-CD30 clones screened by IHC, named 142 and 231, showed reactivity patterns similar to an already-known anti-CD30 mAb (BER-H2), previously investigated as an immunotherapeutic drug in r/r cHL patients [12].